What BPC-157 actually is
BPC-157 ("Body Protection Compound") is a synthetic 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a larger protein found in human gastric juice. The peptide was first isolated in the early 1990s by Sikiric and colleagues at the University of Zagreb. Unlike most peptides, it shows remarkable stability in stomach acid, which has fueled both injectable and oral research formulations.
The mechanism in one paragraph
The most consistent in-vivo signal is angiogenesis — BPC-157 upregulates VEGF (vascular endothelial growth factor) and triggers blood-vessel formation at injury sites. Secondary signals include modulation of the nitric oxide synthase pathway, dopaminergic and serotonergic stabilization, and growth- hormone-receptor expression in tendon fibroblasts. The net effect across animal models is faster soft-tissue repair, particularly in tendon and ligament tissue that humans heal poorly on their own.
What the evidence actually shows (and what it doesn't)
| Indication | Evidence quality | Notes |
|---|---|---|
| Tendon / ligament healing | A (multiple animal studies, mechanism plausible) | Achilles & MCL studies in rats; quadriceps tendon-to-bone healing accelerated |
| Gut ulcer / IBD models | A | Strong rodent IBD model data; orally active |
| NSAID-induced gut injury reversal | A | Reproducible across labs |
| Stroke / brain injury (rodent) | B | Promising; not human-validated |
| Human peripheral neuropathy | C | Only case-report level evidence |
| Human tendon recovery | C | Anecdotes everywhere; published clinical trials are scarce |
The honest limitation is that almost all the high-quality data is animal data. Human trials are sparse, and the FDA explicitly placed BPC-157 on the 503A "do not compound" list in 2022 — followed by an FDA panel in mid-2025 revisiting the question and a Kennedy/HHS push to re-open access in 2026.
Common research dosing
The most-cited research range is 250–500 mcg twice daily, subcutaneous, for 4–8 weeks. Some practitioners inject closer to the injury site for soft-tissue indications; others stay systemic. The compound has a short plasma half-life (~4 hours) but the angiogenic effect appears to outlast plasma clearance.
Stacking
The most common stack is BPC-157 + TB-500 (a 7-residue thymosin-β4 fragment). Mechanistically the two peptides hit different parts of the same repair pathway: BPC-157 drives angiogenesis and neuronal survival; TB-500 drives cell migration and actin polymerization. The half-lives are very different (BPC ~4h, TB-500 ~48h), which is why TB-500 is dosed weekly while BPC is daily. Our half-life visualizer overlays both to show the actual systemic-coverage shape.
Where to learn more
- Sikiric et al, "Stable gastric pentadecapeptide BPC 157", multiple reviews
- The BPC-157 page in our directory lists the most-cited protocols and the molecular profile.
Disclaimer
This is an evidence summary for research purposes. We do not recommend peptide use outside an FDA-approved indication and licensed-physician oversight. Always consult a clinician before initiating any peptide protocol.
Ready to take the next step?
Join our community of elite biohackers and get precise protocols delivered to your inbox.